| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
As a protected amino acid building block, Z-D-Chg-OH does not have a specific biological target. Its utility lies in its role as a synthetic intermediate for the preparation of peptides and peptide-based compounds. The D-configuration and cyclohexyl group can influence peptide conformation, stability, and biological activity when incorporated into peptides. The D-configuration may confer resistance to proteolytic degradation. The cyclohexyl group introduces steric bulk that can restrict peptide flexibility, modulate receptor binding, and enhance hydrophobic interactions. The compound is a valuable tool for structure-activity relationship studies and for developing peptides with improved pharmacological properties, particularly in the field of peptide therapeutics.
|
|---|---|
| ln Vitro |
As a synthetic building block, Z-D-Chg-OH does not have direct in vitro biological activity. Its value is in peptide synthesis and medicinal chemistry. The compound's in vitro activity would be evaluated indirectly through the biological activity of peptides or compounds containing the cyclohexylglycine residue. The D-configuration and cyclohexyl group can influence the activity of the final peptide by affecting receptor binding, enzyme inhibition, or other biological functions. Researchers use this building block to incorporate non-natural amino acids into peptides to modulate their properties. The compound itself is not tested in biological assays but is used as a reagent in chemical synthesis.
|
| ln Vivo |
As a synthetic building block, Z-D-Chg-OH does not have in vivo biological activity. Its value is in peptide synthesis and medicinal chemistry. The compound is not intended for administration to animals or humans. Its biological relevance is indirect, through the peptides or compounds that are synthesized using it. These final products may have in vivo activity depending on their design and target. The compound itself is a chemical reagent used in research and development.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to Z-D-Chg-OH as it is a synthetic building block with no direct biological activity. The compound is characterized by chemical analysis methods such as HPLC for purity assessment (≥98%), NMR for structural confirmation, and optical rotation for enantiomeric purity. The compound's properties as a protected amino acid are evaluated by standard chemical characterization techniques. No enzyme or receptor binding studies have been reported or are relevant for this compound.
|
| Cell Assay |
Cell culture experiments are not applicable to Z-D-Chg-OH as it is a synthetic building block with no direct biological activity. The compound is used in chemical synthesis and is not intended for cell-based assays. Researchers using this compound should focus on its chemical properties and synthetic applications rather than cell-based studies. The compound should be handled with appropriate safety precautions as a chemical reagent.
|
| Animal Protocol |
In vivo animal experiments are not applicable to Z-D-Chg-OH as it is a synthetic building block rather than a therapeutic agent. The compound is not intended for administration to animals. Its biological relevance is indirect, through the peptides or compounds that are synthesized using it. The compound itself is a chemical reagent used in research and development. Researchers should not attempt in vivo administration of this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to Z-D-Chg-OH as it is a synthetic building block rather than a therapeutic agent. The compound is not intended for administration to animals or humans. Its physicochemical properties include molecular weight 291.34, molecular formula C16H21NO4, melting point 103°C, and logP 1.38. The compound is a white to off-white solid powder. Solubility: DMSO ~100 mg/mL (~343.24 mM), H2O <0.1 mg/mL. Storage: powder at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month. These properties are relevant for chemical synthesis rather than pharmacokinetics.
|
| Toxicity/Toxicokinetics |
Toxicology data are not applicable to Z-D-Chg-OH as it is a synthetic building block rather than a therapeutic agent. The compound is not intended for human use, and comprehensive toxicology studies have not been conducted. The compound should be handled with appropriate safety precautions as a chemical reagent. Standard laboratory safety practices should be followed, including use of appropriate personal protective equipment and working in a well-ventilated area. The compound should be stored properly and disposed of in accordance with applicable regulations. Researchers should consult the material safety data sheet (MSDS) for detailed safety information. The compound is for research use only and is not for human use.
|
| Additional Infomation |
Z-D-Chg-OH has CAS number 69901-85-5, molecular formula C16H21NO4, and molecular weight 291.34. It is a glycine derivative and Z-protected D-amino acid, chemically known as (R)-2-(((benzyloxy)carbonyl)amino)-2-cyclohexylacetic acid or N-Z-D-α-cyclohexylglycine. Synonyms: Z-D-Chg-OH, Z-cyclohexyl-D-Gly-OH, CBZ-D-cyclohexylglycine. Purity: ≥98% (HPLC). The compound is a white to off-white solid powder with melting point 103°C. Solubility: DMSO ~100 mg/mL (~343.24 mM), H2O <0.1 mg/mL. Storage: powder at -20°C for 3 years, 4°C for 2 years; in solvent at -80°C for 6 months, -20°C for 1 month. The compound is a valuable building block for peptide synthesis, serving as a glycine analogue for amino acid synthesis and peptide construction. Not for human use; for research purposes only. The Z protecting group can be removed by hydrogenolysis to reveal the free amine for peptide coupling.
|
| Molecular Formula |
C16H21NO4
|
|---|---|
| Molecular Weight |
291.34224
|
| Exact Mass |
157.11
|
| CAS # |
69901-85-5
|
| PubChem CID |
14510026
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
292.8±23.0 °C at 760 mmHg
|
| Melting Point |
103℃
|
| Flash Point |
130.9±22.6 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.510
|
| LogP |
1.38
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
21
|
| Complexity |
346
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O=C(O)[C@@H](C1CCCCC1)NC(OCC2=CC=CC=C2)=O
|
| InChi Key |
CUSYTUPJAYLNFQ-CQSZACIVSA-N
|
| InChi Code |
InChI=1S/C16H21NO4/c18-15(19)14(13-9-5-2-6-10-13)17-16(20)21-11-12-7-3-1-4-8-12/h1,3-4,7-8,13-14H,2,5-6,9-11H2,(H,17,20)(H,18,19)/t14-/m1/s1
|
| Chemical Name |
(2R)-2-cyclohexyl-2-(phenylmethoxycarbonylamino)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~343.24 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.58 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.58 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.58 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4324 mL | 17.1621 mL | 34.3242 mL | |
| 5 mM | 0.6865 mL | 3.4324 mL | 6.8648 mL | |
| 10 mM | 0.3432 mL | 1.7162 mL | 3.4324 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
